Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography–computed tomography: normal patterns, pearls, and pitfalls
| Autor: | W.W. Loughborough, Robert W Foley, Stewart Redman, David Little, Richard Graham |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Fluorine Radioisotopes Biodistribution urologic and male genital diseases 030218 nuclear medicine & medical imaging 03 medical and health sciences Prostate cancer 0302 clinical medicine Positron Emission Tomography Computed Tomography Glutamate carboxypeptidase II Recurrent disease medicine Humans Radiology Nuclear Medicine and imaging Neoplasm Staging Membrane antigen Positron Emission Tomography-Computed Tomography business.industry Prostatic Neoplasms General Medicine Prostate-Specific Antigen Primary cancer medicine.disease 030220 oncology & carcinogenesis Tomography Radiopharmaceuticals Nuclear medicine business |
| Zdroj: | Clinical Radiology. 75:903-913 |
| ISSN: | 0009-9260 |
| DOI: | 10.1016/j.crad.2020.06.031 |
| Popis: | Prostate-specific membrane antigen (PSMA)-based positron-emission tomography (PET)-computed tomography (CT) has shown great promise in prostate cancer imaging. This technique has demonstrated particular utility in the staging of high-risk primary cancer and in the localisation of recurrent disease. The use of fluorine-18 PSMA-1007 is advantageous, as it is excreted via the hepatobiliary system rather than urinary and the longer half-life of fluorine-18 compared to gallium tracers, allows for PSMA imaging in centres without a gallium generator. However, imaging with this tracer is not without flaws and areas of ambiguity remain. In this article, the biodistribution, clinical indications, and pearls of 18F-PSMA-1007 PET-CT in patients with prostate cancer will be discussed, as well as the potential pitfalls in the reporting of these studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect